Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib in patients with Melanoma.

View API

Statements

Source and description
Tafinlar (dabrafenib) [product monograph]. HC.

Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

View API